Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

被引：0

作者：

Karimi, Yasmin H. ^{[1
]}

Thieblemont, Catherine ^{[2
]}

Ghesquieres, Herve ^{[3
]}

Cheah, Chan Y. ^{[4
,5
]}

Clausen, Michael Roost ^{[6
]}

Cunningham, David ^{[7
]}

Jurczak, Wojciech ^{[8
]}

Linton, Kim M. ^{[9
,10
]}

Hutchings, Martin ^{[11
,12
]}

Phillips, Tycel ^{[13
]}

Farooq, Umar ^{[14
]}

Kim, Won Seog ^{[15
]}

Dinh, Minh H. ^{[16
]}

Ghosh, Jagannath ^{[17
]}

Pallai, Rajash ^{[17
]}

Wielgos-Bonvallet, Monica ^{[17
]}

Eskelund, Christian ^{[18
]}

Lugtenburg, Pieternella J. ^{[19
]}

Vose, Julie M. ^{[20
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA

[2] Univ Paris, APHP, Hop St Louis, Hematooncol, Paris, France

[3] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France

[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[5] Univ Western Australia, Nedlands, WA, Australia

[6] Vejle Hosp, Vejle, Denmark

[7] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[8] MSC Natl Res Inst Oncol, Krakow, Poland

[9] Univ Manchester, Christie NHS Fdn Trust, Manchester Canc Res Ctr, Manchester, Lancs, England

[10] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[11] Rigshosp, Copenhagen, Denmark

[12] Univ Copenhagen, Copenhagen, Denmark

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] Univ Iowa, Iowa City, IA USA

[15] Samsung Med Ctr, Seoul, South Korea

[16] AbbVie, N Chicago, IL USA

[17] Genmab, Plainsboro, NJ USA

[18] Genmab, Copenhagen, Denmark

[19] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[20] Univ Nebraska Med Ctr, Omaha, NE USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

ALL; bispecific; large B-cell lymphoma; hematologic malignancy; non-Hodgkin lymphoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-191

引用

页码：S461 / S462

页数：2

共 50 条

[41] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
Diakite, I
Lin, V. W.
Klijn, S.
Navale, L.
Purdum, A. G.
Fenwick, E.
Botteman, M.
van Hout, B.
VALUE IN HEALTH, 2019, 22 : S41 - S41
[42] Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study.
Song, Yuqin
Gao, Quanli
Zhang, Huilai
Fan, Lei
Zhou, Jianfeng
Zou, Dehui
Li, Wei
Yang, Haiyan
Liu, Ting
Wang, Quanshun
Lv, Fangfang
Guo, Haiyi
Yang, Liudi
Huang, Jane
Novotny, William F.
Wang, Yidi
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[43] Epcoritamab versus standard of care in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) - a phase 3 study (EPCORE DLBCL-1)
Hess, G.
Thieblemont, C.
Clausen, M. R.
Lugtenburg, P.
Balari, Sureda A.
Zinzani, P. L.
Wu, J.
Finn, L.
Vindelov, S. D.
Fox, C. P.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 192 - 193
[44] Epcoritamab plus R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Karimi, Yasmin
Abrisqueta, Pau
de Vos, Sven
Nijland, Marcel
Offner, Fritz
Osei-Bonsu, Kojo
Rana, Ali
Archer, Kimberly G.
Song, Yaou
Cordoba, Raul
Falchi, Lorenzo
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[45] GENERATING HEALTH-STATE UTILITY VALUES IN PATIENTS TREATED WITH SECOND-LINE SYSTEMIC THERAPY FOR RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL)
Soare, I. A.
Little, M.
Klijn, S. L.
Elsada, A.
Gibson, A.
Liu, F. F.
Becker, F.
VALUE IN HEALTH, 2023, 26 (12) : S463 - S463
[46] Safety and Efficacy Results From Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (Liso-Cel) In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Abramson, Jeremy
Palomba, M. Lia
Gordon, Leo
Lunning, Matthew
Wang, Michael
Arnason, Jon
Mehta, Amitkumar
Purev, Enkhtsetseg
Maloney, David
Andreadis, Charalambos
Sehgal, Alison
Solomon, Scott
Ghosh, Nilanjan
Albertson, Tina
Garcia, Jacob
Kostic, Aria
Li, Daniel
Kim, Yeonhee
Siddiqi, Tanya
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 215 - 215
[47] Estimation of Long-Term Survival with Tafasitamab plus Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Salles, Gilles
Goswami, Budhaditya
Bagnardi, Vincenzo
Dey, Debarshi
Winderlich, Mark
Ambarkhane, Sumeet
Huang, Dan
Nowakowski, Grzegorz S.
BLOOD, 2020, 136
[48] Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma
Jaeger, Ulrich
Tam, Constantine S.
Borchmann, Peter
McGuirk, Joseph P.
Johansen, Marianne
Waller, Edmund K.
Jaglowski, Samantha
Andreadis, Charalambos
Foley, Stephen R.
Westin, Jason R.
Fleury, Isabelle
Ho, P. Joy
Mielke, Stephan
Teshima, Takanori
Salles, Gilles
Schuster, Stephen J.
He, Fiona
Maziarz, Richard T.
Mayer, Sebastian
Makita, Shinichi
Kersten, Marie J.
Ghosh, Monalisa
Wagner-Johnston, Nina
Kato, Koji
Corradini, Paolo
Goto, Hideki
Colicino, Silvia
Agarwal, Abhijit
Lobetti-Bodoni, Chiara
Bishop, Michael R.
BLOOD ADVANCES, 2022, 6 (16) : 4816 - 4820
[49] Long-term survival outcomes in patients with relapsed/refractory large B-cell lymphoma after treatment of relma-cel: 4-year follow-up in RELIANCE study
Yang, Haiyan
Guo, Ye
Li, Wenyu
Zou, Dehui
Zhou, Daobin
Wang, Zhao
Zhang, Mingzhi
Wu, Jianqiu
Liu, Hui
Xia, Zhen
Yang, Su
Zhou, Zisong
Qin, Yun
Song, Yuqin
Zhu, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[50] Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study
Zinzani, Pier Luigi
Melnichenko, Vladimir
Bouabdallah, Krimo
Walewski, Jan
Majlis, Alejandro
Fogliatto, Laura
Caballero, Dolores
Christian, Beth A.
Gulbas, Zafer
Ozcan, Muhit
Salles, Gilles
Shipp, Margaret A.
Thompson, Seth
Orlowski, Robert J.
Marinello, Patricia
Armand, Philippe
BLOOD, 2020, 136

← 1 2 3 4 5 →